الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 192 |  |  |
| | | from | 192 | | |
Abstract
Background: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease, assessment of SLE disease activity requires both clinical and laboratory assessment. Aim of work: The present study aimed to evaluate some laboratory markers of SLE disease activity including serum ferritin and plasma thrombomodulin levels together with correlation of these markers with the clinical manifestations of SLE disease activity trying to find out the best parameter of disease activity in SLE. Methods: The present study comprised 80 SLE patients, 70 females and 10 males, their ages ranged from 15 to 42 years and they were categorized into 2 groups (group I & II). group I: Recently diagnosed active SLE patients; group II: Inactive SLE patients; Control group: Twenty healthy subjects with matched age and sex. Results: Significant increase in plasma thrombomodulin levels, serum ferritin, anti ds DNA levels and ESR levels in active SLE patients versus inactive SLE patients. Significant positive correlation between thrombomodulin, Ferritin levels and both SLEDAI and SLAM scores. Significant correlation between thrombomodulin levels and presence of renal involvement, vasculitis, arthritis, mucosal ulcer or pericarditis in SLE patients. Conclusion: It was concluded that assessment of SLE disease activity should include both clinical and laboratory parameters. SLEDAI & SLAM scores are good indicators and helpful guide for clinical assessment of disease activity in SLE. Serum ferritin is a useful laboratory marker of SLE disease activity. Also, elevated plasma thrombomodulin level is a sensitive biochemical parameter that could reflect SLE disease activity, in addition, it can define a subset of SLE patients with vasculitis, arthritis, mucosal ulcerations, pericarditis, or renal involvement denoting the degree of severity of the disease and organ involved which is valuable in therapeutic considerations and in anticipating SLE disease prognosis.